‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
The Beacon
Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
30
00:00:00
/ 00:01:35
30